Clinical trial
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
NCT00038844 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038844 |
|---|---|
| Title | Safety and Efficacy of Campath in Nonmyeloablative Transplantation |
| Official title | Safety and Efficacy of Campath in Nonmyeloablative Transplantation |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Lymphoma, Leukemia |
| Intervention type | Drug |
| Interventions | Campath-1 H (Alemtuzumab), Fludarabine, Cyclophosphamide, Rituximab |
| Enrollment | 65 |
| Start date | Jun 1, 2001 |
| Primary completion | Dec 1, 2007 |
| Completion | Sep 1, 2010 |
| First posted | Jun 7, 2002 |
| Last update posted | Nov 2, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: